Literature DB >> 24929212

Polymersomes conjugated to 83-14 monoclonal antibodies: in vitro targeting of brain capillary endothelial cells.

Le-Ha Dieu1, Dalin Wu2, Cornelia G Palivan2, Vimalkumar Balasubramanian1, Jörg Huwyler3.   

Abstract

The blood-brain barrier (BBB) remains an obstacle for many drugs to reach the brain. A strategy to cross the BBB is to modify nanocarrier systems with ligands that bind to endogenous receptors expressed at the BBB to induce receptor-mediated transport. The aim of the present study was to investigate the potential of polymersomes composed of the amphiphilic diblock copolymer poly(dimethylsiloxane)-block-poly(2-methyl-2-oxazoline), PDMS-b-PMOXA, for active targeting of brain capillary endothelial cells. We conjugated PDMS-b-PMOXA polymersomes to the anti-human insulin receptor antibody 83-14 and studied their uptake by brain capillary endothelial cells. Transmission electron micrography and light scattering measurements revealed the self-assembly of the block copolymers into 200 nm vesicles after extrusion. Fluorescence correlation spectroscopy was employed to calculate the number of antibodies coupled to one polymersome. Binding and uptake of the polymersomes conjugated to 83-14 mAb were studied in the human BBB in vitro model hCMEC/D3 expressing the human insulin receptor. Competitive inhibition with an excess of free 83-14 mAb demonstrated the specificity of cellular binding and uptake. Our results suggest that PDMS-b-PMOXA polymersomes conjugated to 83-14 mAb may be suitable nanocarriers for drug delivery to the brain.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Active targeting; Anti-human insulin receptor antibody 83-14; Blood–brain barrier; Insulin receptor; PDMS-b-PMOXA diblock copolymers; Polymersomes

Mesh:

Substances:

Year:  2014        PMID: 24929212     DOI: 10.1016/j.ejpb.2014.05.021

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  8 in total

Review 1.  Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.

Authors:  Iason T Papademetriou; Tyrone Porter
Journal:  Ther Deliv       Date:  2015-08-25

Review 2.  Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.

Authors:  Mayur M Patel; Bhoomika M Patel
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

Review 3.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

Review 4.  Nanomaterial-based blood-brain-barrier (BBB) crossing strategies.

Authors:  Jinbing Xie; Zheyu Shen; Yasutaka Anraku; Kazunori Kataoka; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2019-09-14       Impact factor: 12.479

Review 5.  Progress and perspectives on targeting nanoparticles for brain drug delivery.

Authors:  Huile Gao
Journal:  Acta Pharm Sin B       Date:  2016-06-14       Impact factor: 11.413

6.  Fluorescent bioassay for SARS-CoV-2 detection using polypyrene-g-poly(ε-caprolactone) prepared by simultaneous photoinduced step-growth and ring-opening polymerizations.

Authors:  Tugba Celiker; Faezeh Ghorbanizamani; Hichem Moulahoum; Emine Guler Celik; Kerem Tok; Figen Zihnioglu; Candan Cicek; Ruchan Sertoz; Bilgin Arda; Tuncay Goksel; Kutsal Turhan; Suna Timur; Yusuf Yagci
Journal:  Mikrochim Acta       Date:  2022-04-26       Impact factor: 6.408

7.  Biomimetic artificial organelles with in vitro and in vivo activity triggered by reduction in microenvironment.

Authors:  T Einfalt; D Witzigmann; C Edlinger; S Sieber; R Goers; A Najer; M Spulber; O Onaca-Fischer; J Huwyler; C G Palivan
Journal:  Nat Commun       Date:  2018-03-19       Impact factor: 14.919

8.  Bioinspired Molecular Factories with Architecture and In Vivo Functionalities as Cell Mimics.

Authors:  Tomaž Einfalt; Martina Garni; Dominik Witzigmann; Sandro Sieber; Niklaus Baltisberger; Jörg Huwyler; Wolfgang Meier; Cornelia G Palivan
Journal:  Adv Sci (Weinh)       Date:  2020-01-09       Impact factor: 16.806

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.